Free Newsletter

What's changing in longevity—and what it means for the businesses building it. Read the latest briefing or catch up on earlier issues.

The newsletter is always free.

Latest issue

Newsletter #8 · Oct 7, 2026

Five services your longevity clinic can offer now

Five concrete service paths—strength and mobility, home sleep testing, hearing care, bone assessment, and pelvic-floor treatment—give longevity clinics practical ways to turn a consultation into a useful next step.

Earlier issues

Newsletter #7 · Sep 30, 2026

New ways to protect daily function—from metabolism to memory

Gene therapy reduces a demanding dietary routine, an Alzheimer’s injection brings treatment home, and a retinal trial tests a one-time approach. For developers and care providers, the opportunity is less treatment burden and more daily function—with different evidence and access hurdles at each stage.

Newsletter #6 · Sep 23, 2026

Longevity medicine takes aim at keeping people stronger, longer

Five advances show what could help people stay stronger and do more—and where researchers, drug developers, and rehabilitation providers can build useful products.

Newsletter #5 · Sep 16, 2026

New treatments could expand the longevity market

An aged-dog gene therapy result, a $70 million bet on fat-targeted medicine, and a new care service show where longevity is moving from research toward customers.

Newsletter #4 · Sep 10, 2026

Breakthroughs are not businesses. The value may sit in the layer that delivers them

Blood tests, care services, doctor-led memberships, and specimen infrastructure are starting to determine which prevention products become businesses and which remain science projects.

Newsletter #3 · Sep 1, 2026

The platforms hit their commercial tests

Artificial-intelligence drug discovery, gene editing, cancer screening, and aging-biology companies now face the same test: can they turn technology into products that buyers, regulators, clinicians, and payers will act on?

Newsletter #2 · Aug 26, 2026

The channel decides what scales

Blood draws, insurer pathways, lab reimbursement, artificial-intelligence screening workflows, and employer benefits show why healthspan businesses scale through access points as much as better tests.

Newsletter #1 · Aug 18, 2026

The healthspan market is becoming buyable

Premium prevention, reprogramming capital, a first-human epigenetic-restoration trial, insurance-supported women's midlife care, and Medicare access rules are turning longevity from aspiration into products, proof, payment, and buyer behavior.

Get LongevityBiz in your inbox.